Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 2061309 | Linperlisib free base | 1702816-75-8 | 98% Min. |  |
| Linperlisib, also known as YY-20394 and PI3Kδ-IN-2, is a potent and selective PI3Kδ | ||||
| 2061307 | L006235 | 294623-49-7 | 98% Min. |  |
| L006235 is a potent, reversible cathepsin K inhibitor (IC50 = 0.25 nM) that displays | ||||
| 2051510 | LML-134 | 1542135-76-1 | 98% |  |
| LML134 is an orally active and high selective Histamine 3 receptor (H3R) inverse agon | ||||
| 2042701 | LUT-014 | 2274819-46-2 | 98% Min. | |
| LUT-014 is a B-Raf Inhibitor. Leveraging the paradoxical effect of B-Raf Inhibitors, | ||||
| 2041502 | LSZ102 | 2135600-76-7 | 98% Min. |  |
| LSZ102 is a potent ERα antagonist and degrader. LSZ102 showed ERα degradation IC50 | ||||
| 204502 | LUN42589 | 1848242-58-9 | 98% Min. |  |
| LUN42589, also known as PI3K/mTOR Inhibitor-2, is a potent dual pan-PI3K/mTOR inhibit | ||||
| 204302 | Lerociclib | 1628256-23-4 (free base) | 98% | .png) |
| Lerociclib , also known as G1T38, is an oral, potent and selective CDK4/6 inhibitor f | ||||
| 6111904 | Lemborexant (E-2006) | 1369764-02-2 | 98% Min. |  |
| Lemborexant（CAS 1369764-02-2）is a novel investigational small molecule that inhib | ||||
| 193262 | LY2794193 | 2173037-97-1 | >98% |  |
| LY2794193 is a highly potent and selective mGlu3 receptor agonist. | ||||
| 193123 | LY-3381916 | 2166616-75-5 | >98% |  |
| LY-3381916 is a potent, selective and brain penetrated inhibitor of IDO1 activity, bi | ||||
| 19364 | LR-90 | 245075-84-7 | >98% |  |
| LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory res | ||||
| 19357 | LCL521 | 1226851-11-1 | >98% |  |
| LCL521 is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal a | ||||
| 1922710 | Larotaxel | 156294-36-9 | >98% |  |
| Larotaxel is a semi-synthetic derivative of the taxane 10-deacetylbaccatin III with p | ||||
| 192271 | Leniolisib | 1354690-24-6 | >98% |  |
| Leniolisib, also known CDZ173, is a potent phosphatidylinositol 3-kinase inhibitor (P | ||||
| 192261 | Leuprolide Acetate | 74381-53-6 | >98% |  |
| Leuprolide acetate is the acetate salt of a synthetic nonapeptide analogue of gonadot | ||||
| 192195 | LOXO-292 | 2222755-14-6 | >98% |  |
| LOXO-292 (ARRY-192) is an oral and selective investigational drug in clinical develop | ||||
| 19122 | Lexibulin | 917111-49-0 | >98% |  |
| Lexibulin, also known as CYT997, is a n orally bioavailable small-molecule with tubul | ||||
| 1811302 | LP-211 | 1052147-86-0 | >98% |  |
| LP-211 is a a selective agonist of the serotonin 5-HT7 receptor. | ||||
| 1811213 | LXH254 free base | 1800398-38-2 | >98% |  |
| LXH254 is an orally available inhibitor of all members of the serine/threonine protei | ||||
| 181172 | LY2828360 | 1231220-79-3 | >98% |  |
| LY2828360 is a novel potent, selective, and efficacious CB2 agonist. | ||||
| 1810262 | LP-533401 HCl | 1040526-12-2 | >98% |  |
| LP-533401 HCl is an inhibitor of tryptophan hydroxylase-1 (Tph-1), the initial enzyme | ||||
| 188101 | LP-922761 | 1454808-95-7 | >98% |  |
| LP-922761 is a potent and selective AAK1 inhibitor with an in vitro IC50 value of 4.8 | ||||
| 187165 | LM22B-10 | 342777-54-2 | >98% |  |
| LM22B-10 is a TrkB and TrkC agonist. LM22B-10 exhibits neurotrophic activity (EC50 = | ||||
| 186278 | LY-3200882 | 1898283-02-7 | >98% |  |
| LY-3200882 is an orally active TGFbeta inhibitor. LY3200882 targets transforming grow | ||||
| 186275 | LX2761 | 1610954-97-6 | >98% |  |
| LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays | ||||
| 186156 | L685458 | 292632-98-5 | >98% |  |
| L685458 is a potent and selective γ -secretase inhibitor. | ||||
| 186151 | Lometrexol disodium | 120408-07-3 | >98% |  |
| Lometrexol is a folate analog antimetabolite with antineoplastic activity. | ||||
| 185312 | LB-100 | 1632032-53-1 | >98% |  |
| LB-100 is a protein phosphatase 2A(PP2A)inhibitor. | ||||
| 185252 | LY2881835 | 1292290-38-0 | >98% |  |
| LY2881835 is a potent and selective GPR40 agonist potentially for treatment of type 2 | ||||
| 185212 | LOXO-195 | 2097002-61-2 | >98% |  |
| LOXO-195 is a potent and selective TRK inhibitor capable of addressing potential mech | ||||